BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1370257)

  • 21. Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction.
    Konjević G; Mirjačić Martinović K; Vuletić A; Radenković S
    Biomed Pharmacother; 2010 Dec; 64(10):663-71. PubMed ID: 20800424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.
    Nichols PH; Ward U; Ramsden CW; Primrose JN
    Br J Cancer; 1994 Nov; 70(5):946-9. PubMed ID: 7947102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
    Di Raimondo F; LaPushin R; Hersh EM
    Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of human natural killer cell activity by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine is an early but post-binding event.
    Steele TA; Brahmi Z
    J Immunol; 1988 Nov; 141(9):3164-9. PubMed ID: 3262683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-induced resistance of tumor target cells against lysis by interleukin-2-activated killer cells.
    Takagi S; Minakuchi J; Okawa H; Yata J
    Tohoku J Exp Med; 1989 Feb; 157(2):131-6. PubMed ID: 2496486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordant effect of interferon on natural killer activity and tumor cell sensitivity to lysis in hairy cell leukemia.
    Lahat N; Aghai E; Kotler A; Kinarty A; Sobel E; Gruener N; Froom P
    Blood; 1988 Apr; 71(4):1141-3. PubMed ID: 3258536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro.
    Okamoto M; Kasetani H; Kaji R; Goda H; Ohe G; Yoshida H; Sato M
    Cancer Immunol Immunother; 1998 Dec; 47(4):233-41. PubMed ID: 9875677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of interferons in neuroblastoma. 2: Immunomodulatory effects].
    Handgretinger R; Bruchelt G; Daurer B; Lang P; Dopfer R; Reisfeld RA; Treuner J; Niethammer D
    Klin Padiatr; 1990; 202(4):206-11. PubMed ID: 2118581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
    Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
    Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 3 enhanced interleukin 2-dependent maturation of NK progenitor cells in bone marrow from mice with severe combined immunodeficiency.
    Saikawa Y; Hasui M; Miura M; Tachinami T; Katayama K; Takano N; Miyawaki T; Koizumi S; Taniguchi N
    Cell Immunol; 1989 Nov; 124(1):38-49. PubMed ID: 2805072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of aging on natural killer cell activity and activation by interleukin-2 and IFN-alpha.
    Kutza J; Murasko DM
    Cell Immunol; 1994 Apr; 155(1):195-204. PubMed ID: 7513259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The regulation and biological activity of interleukin 12.
    Lee SM; Suen Y; Qian J; Knoppel E; Cairo MS
    Leuk Lymphoma; 1998 May; 29(5-6):427-38. PubMed ID: 9643557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.
    Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP
    Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells.
    Chehimi J; Valiante NM; D'Andrea A; Rengaraju M; Rosado Z; Kobayashi M; Perussia B; Wolf SF; Starr SE; Trinchieri G
    Eur J Immunol; 1993 Aug; 23(8):1826-30. PubMed ID: 8102101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.
    Brunda MJ; Tarnowski D; Davatelis V
    Int J Cancer; 1986 May; 37(5):787-93. PubMed ID: 2422129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.